Suppr超能文献

单纯疱疹病毒载体介导的无孔 TRPV1 通道基因递送可减轻大鼠膀胱过度活动症和痛觉过敏。

Herpes Simplex Virus Vector-Mediated Gene Delivery of Poreless TRPV1 Channels Reduces Bladder Overactivity and Nociception in Rats.

作者信息

Majima Tsuyoshi, Funahashi Yasuhito, Takai Shun, Goins William F, Gotoh Momokazu, Tyagi Pradeep, Glorioso Joseph C, Yoshimura Naoki

机构信息

1 Department of Urology, University of Pittsburgh School of Medicine , Pittsburgh, Pennsylvania.

2 Department of Urology, Nagoya University Graduate School of Medicine , Nagoya, Japan .

出版信息

Hum Gene Ther. 2015 Nov;26(11):734-42. doi: 10.1089/hum.2015.026. Epub 2015 Aug 31.

Abstract

Increased afferent excitability has been proposed as an important pathophysiology of interstitial cystitis/bladder pain syndrome (IC/BPS) and overactive bladder (OAB). In this study, we investigated whether herpes simplex virus (HSV) vectors encoding poreless TRPV1, in which the segment in C terminus of TRPV1 receptor is deleted, suppress bladder overactivity and pain behavior using a rat model of chemical cystitis. Replication-defective HSV vectors encoding poreless TRPV1 were injected into the bladder wall of adult female Sprague-Dawley rats. Additionally, recombinant HSV virus (vHG) vectors were injected as control. Cystometry (CMG) under urethane anesthesia was performed 1 week after viral injection to evaluate bladder overactivity induced by resiniferatoxin (RTx, a TRPV1 agonist). RTx-induced nociceptive behavior such as licking (lower abdominal licking) and freezing (motionless head-turning) was observed 2 weeks after viral injection. GFP expression in L4/L6/S1 dorsal root ganglia and the bladder as well as c-Fos-positive cells in the L6 spinal cord dorsal horn were also evaluated 2 weeks after viral injection. In CMG, the poreless TRPV1 vector-treated group showed a significantly smaller reduction in intercontraction intervals and voided volume after RTx infusion than the vHG-treated control group. The number of the RTx-induced freezing events was significantly decreased in the poreless TRPV1 group than in the vHG group, whereas there was no significant difference of the number of RTx-induced licking events between groups. The number of c-Fos-positive cells in the DCM and SPN regions of the L6 spinal dorsal horn was significantly smaller in the poreless TRPV1 group than in the vHG group. Our results indicated that HSV vector-mediated gene delivery of poreless TRPV1 had a therapeutic effect on TRPV1-mediated bladder overactivity and pain behavior. Thus, the HSV vector-mediated gene therapy targeting TRPV1 receptors could be a novel modality for the treatment of OAB and/or hypersensitive bladder disorders such as IC/BPS.

摘要

传入神经兴奋性增加被认为是间质性膀胱炎/膀胱疼痛综合征(IC/BPS)和膀胱过度活动症(OAB)的重要病理生理学特征。在本研究中,我们使用化学性膀胱炎大鼠模型,研究编码无孔TRPV1(TRPV1受体C末端片段缺失)的单纯疱疹病毒(HSV)载体是否能抑制膀胱过度活动和疼痛行为。将编码无孔TRPV1的复制缺陷型HSV载体注射到成年雌性Sprague-Dawley大鼠的膀胱壁中。此外,注射重组HSV病毒(vHG)载体作为对照。病毒注射1周后,在乌拉坦麻醉下进行膀胱测压(CMG),以评估树脂毒素(RTx,一种TRPV1激动剂)诱导的膀胱过度活动。病毒注射2周后,观察RTx诱导的伤害性行为,如舔舐(下腹部舔舐)和僵住(静止转头)。病毒注射2周后,还评估了L4/L6/S1背根神经节和膀胱中的绿色荧光蛋白(GFP)表达以及L6脊髓背角中的c-Fos阳性细胞。在CMG中,无孔TRPV1载体治疗组在RTx注入后收缩间期和排尿量的减少明显小于vHG治疗的对照组。无孔TRPV1组中RTx诱导的僵住事件数量明显少于vHG组,而两组之间RTx诱导的舔舐事件数量没有显著差异。无孔TRPV1组L6脊髓背角DCM和SPN区域的c-Fos阳性细胞数量明显少于vHG组。我们的结果表明,HSV载体介导的无孔TRPV1基因递送对TRPV1介导的膀胱过度活动和疼痛行为具有治疗作用。因此,靶向TRPV1受体的HSV载体介导的基因治疗可能是治疗OAB和/或IC/BPS等膀胱过敏疾病的一种新方法。

相似文献

5
Effects of herpes simplex virus vector-mediated enkephalin gene therapy on bladder overactivity and nociception.
Hum Gene Ther. 2013 Feb;24(2):170-80. doi: 10.1089/hum.2011.180. Epub 2013 Feb 14.
6
Effect of herpes simplex virus vector-mediated interleukin-4 gene therapy on bladder overactivity and nociception.
Gene Ther. 2013 Feb;20(2):194-200. doi: 10.1038/gt.2012.24. Epub 2012 Mar 8.

引用本文的文献

1
Next-generation replication-defective HSV vectors for delivery of large DNA payloads.
Mol Ther. 2025 May 7;33(5):2205-2216. doi: 10.1016/j.ymthe.2025.03.055. Epub 2025 Apr 2.
2
Nanotechnology for Pain Management: Current and Future Therapeutic Interventions.
Nano Today. 2021 Aug;39. doi: 10.1016/j.nantod.2021.101223. Epub 2021 Jun 19.
4
Gene Therapy Leaves a Vicious Cycle.
Front Oncol. 2019 Apr 24;9:297. doi: 10.3389/fonc.2019.00297. eCollection 2019.
5
A bright future? Optogenetics in the periphery for pain research and therapy.
Pain. 2018 Sep;159 Suppl 1(Suppl 1):S65-S73. doi: 10.1097/j.pain.0000000000001329.
8
An HSV-based library screen identifies PP1α as a negative TRPV1 regulator with analgesic activity in models of pain.
Mol Ther Methods Clin Dev. 2016 Jun 22;3:16040. doi: 10.1038/mtm.2016.40. eCollection 2016.
9
Novel targeted bladder drug-delivery systems: a review.
Res Rep Urol. 2015 Nov 23;7:169-78. doi: 10.2147/RRU.S56168. eCollection 2015.

本文引用的文献

1
Neural control of the lower urinary tract.
Compr Physiol. 2015 Jan;5(1):327-96. doi: 10.1002/cphy.c130056.
3
Bladder afferent hyperexcitability in bladder pain syndrome/interstitial cystitis.
Int J Urol. 2014 Apr;21 Suppl 1(0 1):18-25. doi: 10.1111/iju.12308.
4
Engineering HSV-1 vectors for gene therapy.
Methods Mol Biol. 2014;1144:63-79. doi: 10.1007/978-1-4939-0428-0_5.
6
Effects of herpes simplex virus vector-mediated enkephalin gene therapy on bladder overactivity and nociception.
Hum Gene Ther. 2013 Feb;24(2):170-80. doi: 10.1089/hum.2011.180. Epub 2013 Feb 14.
8
Targeting TRPV1 for pain relief: limits, losers and laurels.
Expert Opin Investig Drugs. 2012 Sep;21(9):1351-69. doi: 10.1517/13543784.2012.704021. Epub 2012 Jul 11.
9
Mapping of pain phenotypes in female patients with bladder pain syndrome/interstitial cystitis and controls.
Eur Urol. 2012 Dec;62(6):1188-94. doi: 10.1016/j.eururo.2012.05.023. Epub 2012 May 18.
10
Gene therapy for pain: results of a phase I clinical trial.
Ann Neurol. 2011 Aug;70(2):207-12. doi: 10.1002/ana.22446. Epub 2011 Jul 27.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验